cell-mediated immunity

(redirected from T-cell response)
Also found in: Medical, Encyclopedia.

cell-mediated immunity

n.
Immunity involving cells, such as T cells and phagocytes, in contrast with humoral immunity, which involves soluble proteins (antibodies). Also called cellular immunity.

cell′-me`diated immu′nity


n.
immunity conferred to an individual through the activity of T cells, involving the direct destruction of viruses, foreign particles, etc. Compare antibody-mediated immunity.
[1970–75]
References in periodicals archive ?
In addition to directly killing rapidly dividing cancer cells, CTX gets the attention and help of endogenous T cells, and antibiotics reduced that T-cell response, the scientists reported.
Bavarian Nordic A/S (CPH: BAVA), a fully integrated biotechnology company, announced on Thursday that commencement of dosing in the Phase 2 extension study of MVA-BN RSV, a universal vaccine candidate designed to elicit a broad antibody and T-cell response against multiple respiratory syncytial virus (RSV) antigens.
T-cell engaging bispecifics leverage the body's immune system by redirecting the T-cell response towards cancer cells expressing specific tumor antigens.
Activation of the PD-1/PD-L1 pathway essentially functions as an "immune checkpoint" by dampening the T-cell response, preventing overactivation and excess tissue destruction during proinflammatory states.
Peripheral blood mononuclear cells (PBMCs) obtained on day 24 of illness showed a strong specific T-cell response against MERS-CoV spike protein but not against severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein (online Technical Appendix Figure 3, panel C).
Study results indicate that a T-cell response against a mutant protein can be harnessed to mediate regression of a metastatic epithelial cell cancer.
Our vaccine mobilized a T-cell response that was able to overtake the SIV invaders in 50 percent of the cases treated.
To make better vaccines, it may be necessary to activate a T-cell response at the site of an infection, not just in the general circulation," Dr.
Okairos has evaluated its RSV vaccine candidate in well-established preclinical models and found that it stimulates both a strong neutralizing antibody and a robust T-cell response.
The goal of current therapeutic vaccines is to generate a cytotoxic T-cell response, primarily with CD8-positive effector T cells, something that has not been achieved with conventional vaccines that are primarily designed to induce antibodies.
In the proof-of-concept trial, 133 patients infected with hepatitis C virus (HCV) genotype 1 were randomized to either triple therapy comprising the experimental GI-5005 vaccine, which is designed to elicit a T-cell response specific to HCV, along with pegylated interferon alfa-2b plus ribavirin (P/R), or the standard P/R therapy alone.
Years of animal studies on vaccines and other immunotherapies have demonstrated that it's the T-cell response that mediates tumor destruction.